Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients

NCT02439723 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Withdrawal of supply of investigational product

Conditions

Metastatic Solid Malignancies
Locally Advanced Solid Malignancies

Interventions

DRUG: Regorafenib

Sponsor

AHS Cancer Control Alberta

Collaborators

[object Object]